Completed PHASE2 INTERVENTIONAL 6-arm NCT00533377

ACTiF- Assessment of Closed Tibial Fractures

A Randomized, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of CP-533,536 In Subjects With Closed Fracture Of The Tibial Shaft

Sponsor: Pfizer

Conditions Tibial Fractures

Interventions CP-533, 536 CP-533,536 Placebo Standard of Care

Updated 8 times since 2017 Last updated: Feb 15, 2012 Started: Jan 31, 2008 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Tibial Fractures, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ankara, Turkey (Türkiye) , Bangalore, India , Chattanooga, United States , Columbia, United States , Dallas, United States , Durham, United States , Fujisawa-shi, Japan , Glenwood, South Africa , Hamilton, Canada and 35 more locations